Richard O'Donovan, MD
Nephrology · Monroe, LANPI 1467422949
Payments from drug & device makers
Across 508 payments — averaging $1113.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$449K
- Bayer$70K
- Alnylam Pharmaceuticals Inc.$33K
- Travere Therapeutics, Inc.$10K
- AstraZeneca$1K
- Novo Nordisk AS$762
- plus $633 from 9 others
Across 1 payment — averaging $19,212 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$19K
What the payments were for
- Food & beverage$91682%
- Education$20718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 370 | $449,324 |
| Bayer | 32 | $69,888 |
| Alnylam Pharmaceuticals Inc. | 11 | $33,497 |
| Travere Therapeutics, Inc. | 7 | $10,384 |
| AstraZeneca | 11 | $1,177 |
| Novo Nordisk AS | 48 | $762 |
| Amgen | 9 | $162 |
| Vifor Pharma, Inc. | 6 | $143 |
| Novo Nordisk | 4 | $99 |
| OPKO Pharmaceuticals, LLC | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| AbbVie | 2 | $36 |
| Novartis | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
How this compares
$565,664 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 479 | $313,453 |
| VelphoroSucroferric Oxyhydroxide | 45 | $125,024 |
| JardianceEmpagliflozin | 85 | $77,688 |
| AuryxiaFerric Citrate | 23 | $40,636 |
| ProcritEpoetin Alfa | 34 | $40,259 |
| OzempicSemaglutide | 29 | $30,640 |
| RetacritEpoetin Alfa-Epbx | 51 | $28,687 |
| JanuviaSitagliptin Phosphate | 19 | $15,472 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,136 |
| EntrestoSacubitril/Valsartan | 12 | $11,326 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $10,218 |
| KerendiaFinerenone | 13 | $8,492 |
| RenvelaSevelamer Carbonate | 15 | $6,365 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,603 |
| Sevelamer Carbonate | 52 | $5,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,177 | $323,671493 claims |
| Boehringer IngelheimJardiance | $18 | $77,68885 claims |
| Akebia Therapeutics IncAuryxia | $449,324 | $40,63623 claims |
| Novo NordiskOzempic | $99 | $30,64029 claims |
| NovartisEntresto | $22 | $11,32612 claims |
| BayerKerendia | $69,888 | $8,49213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Monroe
- Sreedhara AllaShreveport$1.2M
- Christopher LuscyBaton Rouge$1.1M
- Marwan KaskasShreveport$968K
- Juan Carlos VelezNew Orleans$801K
- Michael RoppoloBaton Rouge$447K
- Anthony BlalockLafayette$350K
- Efrain ReisinNew Orleans$215K
- Raja ZabanehShreveport$208K
- Jones SamuelBaton Rouge$207K
- Robert HooverNew Orleans$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.